Iovance Biotherapeutics (IOVA) Profit After Tax: 2009-2024
Historic Profit After Tax for Iovance Biotherapeutics (IOVA) over the last 13 years, with Dec 2024 value amounting to -$372.2 million.
- Iovance Biotherapeutics' Profit After Tax fell 9.23% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 3.00%. This contributed to the annual value of -$372.2 million for FY2024, which is 16.18% up from last year.
- Latest data reveals that Iovance Biotherapeutics reported Profit After Tax of -$372.2 million as of FY2024, which was up 16.18% from -$444.0 million recorded in FY2023.
- Over the past 5 years, Iovance Biotherapeutics' Profit After Tax peaked at -$342.3 million during FY2021, and registered a low of -$444.0 million during FY2023.
- For the 3-year period, Iovance Biotherapeutics' Profit After Tax averaged around -$404.0 million, with its median value being -$395.9 million (2022).
- Per our database at Business Quant, Iovance Biotherapeutics' Profit After Tax dropped by 15.67% in 2022 and then rose by 16.18% in 2024.
- Iovance Biotherapeutics' Profit After Tax (Yearly) stood at -$342.3 million in 2021, then decreased by 15.67% to -$395.9 million in 2022, then dropped by 12.16% to -$444.0 million in 2023, then grew by 16.18% to -$372.2 million in 2024.